Analysts' ratings for OncoCyte (NASDAQ:OCX) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
1
1
0
0
Last 30D
1
0
0
0
0
1M Ago
1
0
1
0
0
2M Ago
0
1
0
0
0
3M Ago
0
0
0
0
0
Analysts have set 12-month price targets for OncoCyte, revealing an average target of $4.38, a high estimate of $5.00, and a low estimate of $4.00. This upward trend is evident, with the current average reflecting a 21.67% increase from the previous average price target of $3.60.
Investigating Analyst Ratings: An Elaborate Study
A comprehensive examination of how financial experts perceive OncoCyte is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Mike Matson
Needham
Maintains
Buy
$4.25
-
Mike Matson
Needham
Raises
Buy
$4.25
$3.60
Mason Carrico
Stephens & Co.
Maintains
Equal-Weight
$4.00
-
Bruce Jackson
Benchmark
Maintains
Speculative Buy
$5.00
-
Key Insights:
Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related ...Full story available on Benzinga.com
Benzinga
